How to Get BHRT Online: A 5-Step Guide

What Is BHRT and Why Are Women Seeking It Online?

Bioidentical hormone replacement therapy uses hormones whose molecular structure is identical to those produced by the human body, primarily 17-beta-estradiol and micronized progesterone. Demand for telehealth BHRT has risen sharply because in-person menopause specialists are scarce: a 2020 NAMS survey found that fewer than 7,000 U.S. Clinicians felt competent managing menopause [1]. Online platforms close that gap by connecting patients to licensed prescribers across state lines.

Bioidentical vs. Conventional HRT

"Bioidentical" does not automatically mean compounded. FDA-approved bioidentical options include:

• Estradiol patches (Vivelle-Dot, Climara, Minivelle)
• Oral micronized progesterone (Prometrium 100 mg, 200 mg)
• Transdermal estradiol gel (Divigel, EstroGel)
• Vaginal estradiol rings (Estring, Femring)

Compounded BHRT, mixed by a 503A or 503B pharmacy to a prescriber's custom formula, is a separate category. The FDA has stated that compounded hormone products lack the safety and efficacy data of approved drugs [2]. Your prescriber should explain which category they recommend and why.

Why the Telehealth Route Works

A 2022 systematic review in Menopause (N=14 studies) found telehealth hormone consultations produced comparable symptom improvement to in-person care, with higher patient satisfaction scores in 10 of 14 studies [3]. Asynchronous labs drawn at a local Quest or LabCorp location, combined with a video visit, replicate the full clinical workflow without travel time.

Step 1: Confirm You Are a Candidate for BHRT

Before booking any online appointment, run through the core eligibility criteria yourself. BHRT is generally appropriate for women experiencing vasomotor symptoms (hot flashes, night sweats), genitourinary syndrome of menopause (GSM), or documented hormone insufficiency from surgical menopause, premature ovarian insufficiency (POI), or natural perimenopause.

Absolute Contraindications to Know First

The Menopause Society 2023 Position Statement lists the following as contraindications to systemic estrogen therapy [4]:

• Personal history of estrogen-receptor-positive (ER+) breast cancer
• Active or recent arterial thromboembolic disease (stroke, MI within 12 months)
• Active deep vein thrombosis or pulmonary embolism
• Unexplained vaginal bleeding
• Known or suspected estrogen-dependent neoplasia

If any of these apply, a telehealth provider should not prescribe systemic estrogen, and any platform that skips this screening is operating below the standard of care.

Who Is a Strong Candidate

Women aged 45 to 60 who are within 10 years of menopause onset and who have no contraindications get the most favorable benefit-to-risk ratio, per the NAMS 2022 Hormone Therapy Position Statement [4]. The WHI Memory Study follow-up (mean age at enrollment 63) does not apply to this younger, recently menopausal cohort.

Step 2: Choose a Licensed Telehealth BHRT Provider

Choosing the right platform is the single decision with the most downstream consequences. A reputable provider will always require a lab panel before prescribing, offer FDA-approved formulations as a first line, and have a board-certified physician or nurse practitioner supervising every prescription.

Questions to Ask Before You Book

Ask every platform you are evaluating these four questions:

1. Is the prescriber licensed in my state and board-certified in ob-gyn, endocrinology, or internal medicine?
2. Do you require baseline blood work before issuing a hormone prescription?
3. Will you offer FDA-approved estradiol and progesterone as a first-line option, or only compounded preparations?
4. What is your protocol if my labs show an unexpected finding, such as elevated prolactin or a thyroid abnormality?

Platforms that cannot answer all four questions clearly should be skipped.

Red Flags in Provider Selection

Avoid any telehealth service that prescribes hormones without labs, sells proprietary compounded pellets as the only option, or does not include follow-up monitoring in the care plan. The Endocrine Society's 2015 Clinical Practice Guideline on androgen therapy in women emphasizes individualized dosing guided by serum levels, not symptom scores alone [5].

Verifying Credentials

Check the prescriber's license at your state medical board's public verification tool. In the U.S., the Federation of State Medical Boards (FSMB) aggregates these lookups at docinfo.org. A five-minute license check can prevent a significant problem down the road.

Step 3: Complete Your Symptom Intake and Lab Panel

After booking, most platforms send a detailed intake questionnaire covering menstrual history, symptom severity (often using the validated Menopause Rating Scale or Greene Climacteric Scale), family history, and current medications. Fill this out completely. Incomplete intake forms delay prescriptions.

The Core Lab Panel Explained

A responsible BHRT workup includes the following tests, drawn at a fasting baseline:

| Lab Test | Why It Matters | |---|---| | FSH | Confirms menopausal status (FSH >40 mIU/mL on two draws 4 to 6 weeks apart) | | Estradiol (E2) | Baseline before supplementation; goal range on therapy typically 40 to 100 pg/mL | | Progesterone | Rules out luteal-phase deficiency in perimenopausal women | | Total and Free Testosterone | Guides androgen add-on decisions | | SHBG | Affects bioavailable estrogen and testosterone calculations | | TSH, Free T4 | Thyroid dysfunction mimics many menopause symptoms | | CBC | Screens for anemia, polycythemia (relevant with testosterone) | | CMP (metabolic panel) | Liver and kidney function before oral hormones | | Fasting lipid panel | Cardiovascular baseline | | HbA1c or fasting glucose | Insulin resistance affects hormone metabolism |

If the platform does not order at minimum FSH, estradiol, and a thyroid panel, that is a gap in care.

How to Get Labs Done Quickly

Most telehealth platforms partner with LabCorp or Quest Diagnostics. After your video intake, you receive a digital lab requisition by email. Walk-in appointments at either network are usually available within 48 hours and results return in two to three business days. Total turnaround from intake visit to results in hand: five to seven days in most U.S. Markets.

Step 4: Work With Your Prescriber to Build a Treatment Plan

Once labs are back, your prescriber schedules a results consultation, typically 20 to 30 minutes by video. This visit is where your regimen is designed.

Standard Starting Doses

The Menopause Society recommends starting at the lowest effective dose and titrating based on symptom response and follow-up serum levels [4]. Typical starting regimens include:

• Transdermal estradiol patch: 0.025 mg/day to 0.05 mg/day, changed twice weekly
• Transdermal estradiol gel (EstroGel): 0.75 mg/day (one pump) applied to the arm
• Oral micronized progesterone (Prometrium): 200 mg nightly for 12 days per cycle (cyclic) or 100 mg nightly continuously
• Vaginal estradiol (Estring ring): 2 mg ring releasing 7.5 mcg/day, replaced every 90 days for GSM only

Testosterone is sometimes added for hypoactive sexual desire disorder at 0.5 to 2 mg/day transdermal (off-label in the U.S.; approved in Australia as Androfeme). The Endocrine Society guideline supports offering testosterone to postmenopausal women with HSDD after ruling out other causes [5].

The Uterus Rule

Any woman with an intact uterus who receives systemic estrogen must also receive progestogen. Unopposed estrogen raises endometrial cancer risk by 2- to 12-fold depending on dose and duration, per a 1995 NEJM meta-analysis that remains the bedrock reference [6]. This is non-negotiable. A telehealth provider who prescribes estrogen without progesterone to a woman with a uterus is violating a basic standard of care.

Compounded vs. FDA-Approved: Making the Decision Together

Use this decision framework with your prescriber to choose between FDA-approved and compounded BHRT:

Start with FDA-approved if: your dose falls within commercially available strengths, you have insurance that covers it, and you have no documented allergy to excipients (peanut oil in Prometrium is relevant for nut-allergic patients).

Consider compounded if: you need a dose or delivery route not commercially available, you have a confirmed excipient allergy, or you are combining multiple hormones in a single preparation for adherence reasons. Verify the pharmacy holds an NABP (National Association of Boards of Pharmacy) .pharmacy accreditation or is an FDA-registered 503B outsourcing facility.

Compounded bioidentical hormone combinations (CBHTs) are not FDA-approved and lack the standardized potency testing of approved products. The FDA has documented potency variability in compounded hormone products ranging from 67% to 268% of labeled dose [2].

Step 5: Monitor Progress and Adjust Every 3 to 6 Months

Starting BHRT is not a one-time event. Ongoing monitoring is what separates a safe, effective protocol from a poorly managed one. Build this into your plan from day one.

What Gets Tested at Follow-Up

At the 8- to 12-week mark, your provider should recheck serum estradiol and, if testosterone was added, free testosterone and hematocrit. Symptom reassessment using the same validated scale used at baseline lets you and your clinician track objective change rather than relying on memory.

At 6 months, a full repeat of the baseline panel is reasonable. Annually, the following are standard:

• Mammogram (women 40+, or per individualized screening plan per USPSTF 2024 recommendations) [7]
• Pelvic exam with cervical cytology on the schedule recommended by ACOG
• Fasting lipid panel
• Blood pressure and weight

When to Call Your Provider Between Visits

Contact your telehealth team promptly if you experience:

• Breast pain or a new breast lump
• Unscheduled vaginal bleeding after six months of continuous combined therapy
• New onset leg swelling, pain, or redness (possible DVT)
• Severe headaches or visual changes

These symptoms do not necessarily mean you must stop therapy immediately, but they require same-day clinical assessment, not waiting until your next scheduled check-in.

How Long Should BHRT Continue?

Duration of therapy is individualized. The NAMS 2022 position statement no longer endorses an arbitrary five-year cap [4]. For women who began therapy before age 60 and within 10 years of menopause, the absolute risks of cardiovascular events and breast cancer remain small, and quality-of-life benefits can justify continuation with annual reassessment. Women who started after age 60 or more than a decade post-menopause carry a different risk profile and warrant closer review.

Cost, Insurance, and What to Expect at the Pharmacy

Telehealth BHRT visits typically cost $75 to $250 per consultation without insurance. Prescription costs vary widely by formulation:

• Generic transdermal estradiol patch (0.05 mg): approximately $30 to $60 per month with GoodRx at most chain pharmacies
• Prometrium 100 mg (30 capsules): approximately $40 to $90 generic
• Compounded BHRT (custom gel or troche from a compounding pharmacy): $80 to $200 per month, rarely covered by insurance

Medicare Part D covers FDA-approved hormone products. Many commercial insurance plans cover generic estradiol and progesterone at Tier 1 or Tier 2. Compounded hormones are almost never covered.

GoodRx, NeedyMeds, and manufacturer patient-assistance programs can significantly lower out-of-pocket costs for approved formulations.

Safety Evidence: What the Data Actually Show

Understanding the clinical trial field helps you have an informed conversation with your prescriber rather than relying on fear or anecdote.

The WHI Data in Context

The Women's Health Initiative (WHI) 2002 publication alarmed clinicians and patients alike [8]. But the WHI enrolled women with a mean age of 63, most of whom were 10 or more years past menopause. Applying those findings to a 50-year-old who just entered perimenopause is a methodological error now formally recognized as the "timing hypothesis" or "window of opportunity."

A 2012 re-analysis of WHI data (N=27,347 combined) showed that women aged 50 to 59 who used conjugated equine estrogen alone had a 23% lower rate of MI compared to placebo [9]. That number is specific and worth knowing.

The ELITE Trial

The Early versus Late Intervention Trial with Estradiol (ELITE, N=643) randomized women to oral estradiol 1 mg/day plus vaginal progesterone or placebo, stratified by years since menopause [10]. Women who started within six years of menopause showed significantly slower progression of carotid intima-media thickness (CIMT), a marker of atherosclerosis, compared to late starters. CIMT in the early-start group was 0.0044 mm/year lower than placebo (P<0.008).

Breast Cancer Risk

The Collaborative Group on Hormonal Factors in Breast Cancer (2019, N=108,647 breast cancer cases) found that five years of combined estrogen-progestogen therapy was associated with one additional breast cancer case per 50 users over 20 years of follow-up [11]. That absolute risk is real and should be disclosed, but it is small and context-dependent. Micronized progesterone may carry a lower breast cancer risk than synthetic progestins, per observational data from the French E3N cohort (N=80,377), though randomized trial confirmation is still pending [12].

"The risk-benefit calculation for hormone therapy must be individualized based on a woman's age, time since menopause, symptom burden, and personal risk factors," reads the NAMS 2022 Position Statement [4]. That framing captures the clinical consensus.

Practical Tips for a Smooth Telehealth Experience

Getting the most from an online BHRT visit requires some preparation on your end.

Keep a symptom diary for two weeks before your first appointment. Log hot flash frequency, sleep disruption, mood changes, and any vaginal symptoms. Quantified symptom data gives your prescriber more to work with than a general report of "feeling off."

Gather your medical history in advance. Relevant items include any prior mammograms and results, a list of current medications and supplements (note that St. John's Wort and some anticonvulsants affect hormone metabolism), and any prior hormone therapy or OCP history.

Check your state's telehealth prescribing rules. Most states allow prescribers to issue controlled substances and hormone prescriptions after a synchronous video visit without a prior in-person exam, following the DEA's 2023 telehealth framework. A handful of states retain stricter requirements.

Set a pharmacy preference early. If you want a specific compounding pharmacy, confirm the prescriber works with that pharmacy before your consultation, not after.

A Note on Pellet Therapy

Subcutaneous hormone pellets are a delivery method offered by some BHRT providers, where compressed pellets of estradiol or testosterone are inserted under the skin of the buttock every three to six months. Pellets are always compounded. They carry unique risks including pellet extrusion (reported in 2 to 10% of insertions), difficulty reversing supraphysiologic testosterone levels, and dose inflexibility once inserted.

The Endocrine Society does not include pellets in its recommended delivery methods for women [5], and no large randomized controlled trial has compared pellets favorably to transdermal or oral formulations on patient outcomes. Telehealth providers who recommend pellets as a first-line treatment without presenting alternatives deserve scrutiny.